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Abstract
Background: The innate immune system is the first line of defense against viruses by inducing expression of cytokines and
chemokines. Many pandemic influenza H1N1 virus [P(H1N1)] infected severe cases occur in young adults under 18 years old
who were rarely seriously affected by seasonal influenza. Results regarding host cytokine profiles of P(H1N1) are ambivalent.
In the present study we investigated host cytokine profiles in P(H1N1) patients and identified cytokines related to disease
severity.
Methods and Principal Findings: We retrieved 77, 59, 26 and 26 sera samples from P(H1N1) and non-flu influenza like
illness (non-ILIs) cases with mild symptoms (mild patients), P(H1N1) vaccinees and healthy individuals, respectively. Nine and
16 sera were from hospitalized P(H1N1) and non-ILIs patients with severe symptoms (severe patients). Cytokines of IL-1, IL-2,
IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IFN-c and TNF-a were assayed by cytokine bead array, IL-17 and IL-23 measured with ELISA.
Mild P(H1N1) patients produced significantly elevated IL-2, IL-12, IFN-c, IL-6, TNF-a, IL-5, IL-10, IL-17 and IL-23 versus to
healthy controls. While an overwhelming IL-6 and IL-10 production were observed in severe P(H1N1) patients. Higher IL-10
secretion in P(H1N1) vaccinees confirmed our observation that highly increased level of sera IL-6 and IL-10 in P(H1N1)
patients may lead to disease progression.
Conclusion and Significance: A comprehensive innate immune response was activated at the early stage of P(H1N1)
infection with a combine Th1/Th2/Th3 cytokines production. As disease progression, a systemic production of IL-6 and IL-10
were observed in severe P(H1N1) patients. Further analysis found a strong correlation between IL-6 and IL-10 production in
the severe P(H1N1) patients. IL-6 may be served as a mediator to induce IL-10 production. Highly elevated level of sera IL-6
and IL-10 in P(H1N1) patients may lead to disease progression, but the underlying mechanism awaits further detailed
investigations.
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Introduction
Pandemic H1N1/09A [P(H1N1)] of swine origin has led to a
global spread of pandemic in 2009 and 2010. This new pandemic
strain is of particular concern because of its efficient person-to-
person transmission and reassortments of potentially increased
virulence. Experiments have indicated that P(H1N1) increases
morbidity in human [1,2,3]. Since P(H1N1) can persist in the
human population, it can potentially cause even more severe
clinical consequences.
The innate immune system, the first line of defense against
invading viruses, involves two types of cytokine responses: a
proinflammatory response and an antiviral response. Inflamma-
tory cytokines and chemokines play a role in the pathogenesis of
virus infection in animals and humans [4]. Humans infected with
highly virulent influenza viruses together with aberrant and
excessive cytokine production are linked to morbidity and
mortality. Over-production of specific inflammatory cytokines,
such as the tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6
and IL-10, as well as the polymorphonuclear neutrophil CC
chemokine (chemokine) IL-8, is the hallmark of viral infection [5].
A cytokine-mediated inflammatory response, characterized by
hyper-induction of proinflammatory cytokine production, also
known as hypercytokinemia, has been well documented as an
important player in the disease progression and the ultimate death
of patients infected by most seasonal influenza. Excessive cytokines
(IL-6, TNF-a and IFN-c), or elevated cytokine (IL-6, IL-12, and
IFN-c) levels have been observed in community acquired acute
seasonal influenza A illness [6], or in severe seasonal influenza
patients [7]. However, the innate immune response related to
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relation to the disease severity remain thus far unclear.
Results from previous studies regarding the host cytokine profile
in cell lines or patients infected with P(H1N1) are ambivalent.
O ¨ sterlund et al [8] reported a poor proinflammatory cytokine gene
expression in human monocyte-derived dentritic cells (DCs) and
macrophages infected with P(H1N1). Mukherjee et al [9] found
that the expression of IL-8 and IL-4 was not induced in the A549
cells infected with P(H1N1). A robust Th17 and Th1 cytokine
secretion was reported from severe patients infected with P(H1N1)
[10]. Therefore, the conflicting available data from different
studies have indicated the complexicity of P(H1N1) virus infection,
and warrant the necessity of further studies.
Similar to most strains of seasonal influenza, P(H1N1) infection
is self-limiting and uncomplicated with mild clinical symptoms,
such as fever and acute upper respiratory track infection symptoms
in the great majority of the patients [11]. A small percentage of
patients, however, can develop more complicated and severe
symptoms, such as pneumonia or acute respiratory distress
syndrome, requiring hospitalization [11,12]. Young adults under
the age of 18 years, an age group rarely severely affected by
seasonal influenza, have a disproportionally high risk of falling into
this small percentage [11,12,13]. Surveillance data in Japan also
reported that most cases of P(H1 N1) infection with severe
symptoms and hospitalizations occurred in individuals aged 5–14
years [14]. Reports from the Centers for Disease Control (CDC)
showed that the P(H1N1) virus took a heavier toll among
chronically ill children than the seasonal flu usually did. Several
hypotheses to explain this phenomenon were advocated, including
bacterial infection, down-regulation of type 1 interferon expres-
sion, apoptosis and hyperinduction of proinflammatory. Studies
have suggested that the severe symptoms of P(H1N1) infection in
young adults may be caused by an excessive immune response
[15]. However, more data are needed for better understanding.
In an attempt to elucidate the innate immune response to
P(H1N1) infection and to gain further insight into cytokine
mediated pathogenesis, we retrospectively investigated the expres-
sion levels of a panel of serum cytokines and chemokines in
different groups of patients and controls, including severe and mild
patients infected with P(H1N1), severe and mild patients with non-
influenza like illness (non-ILIs), vaccinees immunized with
P(H1N1) vaccine and healthy individuals. The results derived
from this study may help understand the pathogenic events leading
to poor outcomes related to P(H1N1) infection, and design rational
strategies for diagnosis and treatment.
Results
Patients’ characteristics
P(H1N1) cases (77) and non-ILIs patients (59) were all
quarantined cases investigated during 2009 influenza pandemic
period. The health control individuals (26) were selected from
study subjects of 2009 P(H1N1) herd immunity survey. The
majority (91%, 70/77) P(H1N1) cases and (88%, 52/59) non-ILIs
patients were isolated on the day of fever onset (Chi-sqare test,
p=0.599) and the others on the second day. The age median of
P(H1N1) patients and non-ILIs cases were 16 [Inter Quantile
Range (IQR): 21–27] and 28 (IQR: 21–39), respectively
(p=0.017, Kruskal Wallis test). Age group of 5,20 year old
consisted of 46.1% (35/77) of total P(H1N1) cases, or 23.7% (14/
59) of total non-ILIs patients, p=0.006, demonstrating a
disproportionally high infection rate in these age groups. There
was no statistical difference regarding gender distribution in both
groups. Compared with the non-ILIs cases whose median body
temperature was 37.8uC (IQR: 37.6–38.1), P(H1N1) patients
experienced higher fever with a median body temperature of
38.1uC (IQR: 37.8–38.8uC), (p=0.0004, Kruskal Wallis test),
indicating a unique pathogenic nature of P(H1N1).
Both severe P(H1N1) and non-ILIs patients were hospitalized
patients from year 2011. Detailed characteristics and clinical
manifestation were summarized in Table 1. The age and gender
distribution in both groups are similar (p=0.694) and (p=0.673).
The pathological chest x-ray within 24 hours of onset of the
symptoms was taken in all patients. The majority of the patients
suffered from fever. The respective body temperature in severe
P(H1N1) patients and non-ILIs were 38.5uC (IQR: 37.9–38.8uC)
and 38.1uC (IQR: 37.7–39.0uC), p=0.673), respectively. Cough
was common in both groups. However, P(H1N1) cases more
frequently had productive cough (p=0.062), while non-flu ILIs
cases had more dry cough (p=0.008). Severe P(H1N1) patients
had higher rate of gastrointestinal symptoms, with 55.5% (5/9) of
P(H1N1) and 12.5% (2/16) of non-ILIs patients reported diarrhea,
(p=0.034), respectively.
Characteristics and antibody level of P(H1N1) vaccinees and
healthy control were demonstrated in Table 2. The two groups
had similar age (p=0.226) and gender (p=0.572) distributions.
The geomean of haemoglutinin inhibition (HI) antibody titer of
P(H1N1) vaccinees was about 220.3 IU/ml, which was markedly
higher than that of healthy controls (1.8 IU/ml, p,0.0001).
Sera cytokines of patients with mild symptoms
Seventy seven P(H1N1) patients and 59 non-ILIs patients, both
with mild symptoms, were included in this study, and 26 sera
samples from health individuals were collected as healthy controls.
The levels of sera IFN-c, TNF-a, IL-1, IL-2, IL-4, IL-5, IL-6, IL-
8, IL-10, IL-12, IL-17 and IL-23 were measured. Sera level of IL-8
in non-ILIs cases were significantly higher (p=0.005) (Figure 1B)
than that of healthy controls. Although the levels of sera IL-1, IL-
12, and TNF-a, Th2 cytokine of IL-10 in non-ILIs patients were
higher than those of healthy controls, no statistic differences were
observed (Figure 1A). P(H1N1) patients secreted significantly
higher level of sera Th1 cytokines of, IL-2 (p=0.022), IL-12
(p=0.049), IFN-c (p=0.013), IL-6 (p=0.013) and TNF-a
(p=0.000), Th2 cytokine of IL-5 (p=0.044) and IL-10
(p=0.017) than healthy controls (Figure 1A and 1B). When
compared with the data of the non-ILIs, P(H1N1) patients
produced higher level of the sera Th1 cytokines of IFN-c
(p=0.002), IL-6 (p=0.000) and TNF-a (p=0.003), Th2 cytokine
of IL-5 (p=0.005) and IL-10 (p=0.000).
Since the sera levels of IL-17 and IL-23 were too low to be
detected in most samples, we used the positive detection rate to
present the data. The respective positive detection rate of IL-17
from P(H1N1) patients, non-ILIs cases and healthy controls were
19.5% (15/77), 16.9% (10/59) and 3.8% (1/26), respectively
(Fisher exact chi-square test, p=0.049). The respective positive
detection rate of IL-23 of P(H1N1) patients, non-ILIs cases and
healthy controls were 13.0% (10/77), 37.3% (22/59) and 0% (0/
26) (MH chi-square test, p=0.001), respectively. Among the
positive samples, the IL-17 and IL-23 levels were higher in the
P(H1 N1) patients than those of health controls.
These results suggested that P(H1N1) infection induced an early
and comprehensive innate immune response with higher levels of
Th1, Th2 and Th3 cytokines secretion.
Sera cytokines of severe P(H1N1) patients and severe
non-ILIs cases
Nine severe P(H1N1) patients and 16 non-ILIs were from the
hospitalized patients of year 2011. Compared with the severe non-
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increased sera production of IL10 (p=0.032) and IL-6 (p=
0.048) respectively, and reduced production of IL-8 (p=0.048).
Statistic difference was not observed in the sera levels of IFN-c,
TNF-a, IL-1, IL-2, IL-4, IL-5 and IL-12 between the two groups
(Figure 2A and 2B), as well as in IL-17 and IL-23.
These results indicated that the severe P(H1N1) patients
secreted higher level of sera IL-6 and IL-10 than that of the
severe non-ILIs patients,which is an indication of a unique
pathogenicity of P(H1N1) infection.
Sera cytokines of P(H1N1) vaccinees and healthy controls
To identify the relationship between up-regulated cytokine
levels and P(H1N1) infection, 26 sera samples with a hemagglu-
tinin inhibition (HI) antibody titer for P(H1N1) higher than
40 IU/ml were collected 1 month after P(H1N1) vaccination, and
26 sera samples with a HI antibody titer for P(H1N1) lower than
40 IU/ml were randomly selected as healthy controls. Cytokines
and chemokines levels in sera were measured in both groups.
P(H1N1) vaccinees secreted markedly higher level of sera IL-12
(p=0.050) and IL-10 (p=0.018) than those of healthy controls
(Figure 3A and 3B). There were no difference in sera Th1
cytokines (IFN-c, IL-1, IL-2, IL-6 and TNF-a), Th2 cytokines (IL-
4, IL-5) and chemokine IL-8 between P(H1N1) vaccinees and
healthy controls. Except one case of low level positive detection of
IL-17 among 26 healthy controls there were no positive detections
for sera Il-17 and IL-23 in all other cases including the vaccinees
and healthy controls.
These results indicated that sera IL-10 was elevated not only in
those individuals infected with P(H1N1) virus with mild and severe
symptoms, but also in those immunized with P(H1N1) vaccine,
indicating the role of IL-10 in P(H1N1) infection.
Table 1. Characteristics and medical conditions of severe P(H1N1) patients and non-ILIs cases in Shanghai from year 2011.
Characteristics No. patients of P(H1N1) (%) No. patients of non-ILIs (%) p Value
Confirmed Patients 9 16
Demographic Information
Age median (min-max) 2 y(7 m–10 y) 3 y(9 m–12 y) 0.694
Male 6(66.7) 12(75.0) 0.673
Clinical Manifestation
{BT (95% CI) 38.5(37.9–38.8) 38.1(37.7–39.0) 0.673
X-ray change 9(100.0) 16(100.0)
Fever 8(88.9) 15(93.7) 0.6
Productive cough 8(88.9) 7(43.7) 0.062
Dry cough 1(11.1) 8(50.0) 0.008
Running nose 2(22.2) 5(31.25) 0.501
Pharyngalgia 2(22.2) 3(18.7) 0.609
Dyspnea 7(77.8) 8(50.0) 0.176
Malaise 3(33.3) 2(12.5) 0.23
Headache 1(11.1) 0 0.36
Chest pain 1(11.1) 1(6.2) 0.6
Muscle aches 1(11.1) 0 0.36
Abdominalgia 2(22.2) 0 0.12
Diarrhea 5(55.5) 2(12.5) 0.034
{BT(95%CI): Body Temperature (95% Confidence Interval). The statistic difference of age distribution between the two disease groups was tested by the Kruskal-Wallis
chi-square test. Differences of gender and clinical symptoms were tested by the Fisher’s exact chi-square test.
doi:10.1371/journal.pone.0028680.t001
Table 2. Characteristics and antibody levels of P(H1N1) vaccinees and healthy subjects from year 2009 in Shanghai.
Characteristics No. of healthy subjects (%) No. of P(H1N1) vaccinees (%) p Value
Study subjects 26 26
Age (median; IQR)* 32(27–42) 39(30–46) 0.226
Male 11(42.3) 9(34.6) 0.572
Geomean of P(H1N1) HI Antibody titer (IU/ml) 1.8 220.3 0.000
IL-17 positive detection 3.8%(1/26) Under detectable
IL-23 positive detection Under detectable Under detectable
*IQR: Inter Quantile Range. The statistic difference of age distribution between the two study groups was tested by the Kruskal-Wallis chi-square test; Difference of
gender was tested by the Fisher’s exact chi-square test. Data of antibody titer were log transformed, and difference of antibody titer from two groups was measured by
T test.
doi:10.1371/journal.pone.0028680.t002
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To elucidate the association between cytokine production and
disease severity, we analyzed the sera cytokine levels of patients
with mild and severe symptoms in P(H1N1) and non-ILIs patients.
Compared with the mild P(H1N1) patients, severe P(H1N1)
patients produced markedly higher levels of IL-6 (p=0.030) and
IL-10 (p=0.0006), but significantly lower levels of IFN-c
(p=0.022), TNF-a (p=0.033) and IL-5 (p=0.001) (Figure 4A
and 4B), respectively. No statistic difference was observed in sera
levels of cytokines of IFN-c, TNF-a, IL-1, IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12, IL-17 and IL-23 and chemokine IL-8 (Figure 4C
and 4D) between non-ILIs patients with mild and severe
symptoms. Thus, our results suggested that elevated sera levels
of IL-6 and IL-10 may relate to the disease progression and
severity in patients infected with P(H1N1).
Sera levels of IL-6 and IL-10 and body temperature in
P(H1N1) patients
Since IL-6 may have both pro- and anti-inflammatory effects on
macrophages, and IL-10 is a potent inhibitor for macrophage
function, we analyzed the association between IL-6 and IL-10
production in all P(H1N1) patients. In addition, the association
between IL-6 level and body temperature was also analyzed. In
the mild P(H1N1) patients from year 2009, we observed a positive
correlation between patients’ sera IL-6 level and body temperature
with a correlation coefficient of 0.837, p,0.0001 (Figure 5A), but
no correlation between patients’ sera IL-6 and IL-10 with a
correlation coefficient of 0.186, p=0.104 (Figure 5B). In severe
P(H1N1) patients, no correlation between sera IL-6 level and body
temperature was observed with a correlation coefficient of 0.015,
p=0.965 (Figure 5C). However, a positive correlation between IL-
6 and IL-10 levels was observed with a correlation coefficient of
0.847, p=0.004 (Figure 5D) in these patients.
Discussion
The innate immune system serves as the first line to fight
against pathogens. Production of cytokines and chemokines is
the first ramification of activation of the innate immune cells.
The interleukins, together with IFN-c,T N F - a and other
Figure 1. Sera cytokine levels of P(H1N1) patients, non-ILIs and healthy controls. Geomean production of IFN-c, IL-1, IL-2, IL-4, IL-5, IL-10, IL-
12, TNF-a, IL-6 and IL-8 expression in the sera samples from pandemic H1N1 influenza [P(H1N1)] (white bars, n=77), non-flu influenza like illness (non-ILIs)
(Light grey bars, n=59) and healthy controls (Dark grey bars, n=26) were graphed as figure 1Aand 1B. Bars representgeomeans 695% ConfidenceInterval
(CI). * Indicates significant differences (p#0.05) between P(H1N1) patients and non-ILIs patients, or between P(H1N1) patients and healthy controls.
doi:10.1371/journal.pone.0028680.g001
Figure 2. Sera cytokine levels of severe P(H1N1) and non-ILIs patients of 2011. Geomean production of IFN-c, IL-1, IL-2, IL-4, IL-5, IL-10, IL-
12, TNF-a, IL-6 and IL-8 expression in sera samples from severe P(H1N1) patients (White bars, n=9) and severe non-ILIs (Grey bars, n=16) were
graphed as figure 2A and 2B. Bars represent geomeans 695% CI. * Indicates significant differences (p#0.05) between 2 study groups.
doi:10.1371/journal.pone.0028680.g002
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immune response, and play a role in activating the adaptive
immune response [16].
Up-regulated levels of IL-1, IL-6, IL-12, and IL-23 were
reported to be related to increased responses to infection, such as
fever, phagocytic cell recruitment and blood vessel permeability.
Figure 3. Sera cytokine levels of P(H1N1) vaccinees and healthy controls. Geomean production of IFN-c, IL-1, IL-2, IL-4, IL-5, IL-10, IL-12, TNF-
a, IL-6 and IL-8 levels in sera samples from P(H1N1) vaccinees (Grey bars, n=26) and healthy controls (White bars, n=26) were graphed as figure 4A
and 4B. Bars represent geomeans 695% CI.* Indicates significant differences (p#0.05) between 2 study groups.
doi:10.1371/journal.pone.0028680.g003
Figure 4. Sera cytokine levels between people got mild and severe infection. Geomean production of IFN-c, IL-1, IL-2, IL-4, IL-5, IL-10, IL-12,
TNF-a, IL-6 and IL-8 in sera samples from severe (Grey bars, n=9) and mild P(H1N1) patients (White bars, n=77) were graphed as figure 4A and 4B.
Geomean production of IFN-c, IL-1, IL-2, IL-4, IL-5, IL-10, IL-12, TNF-a, IL-6 and IL-8 in sera samples from severe (Grey bars, n=16) and mild non-ILIs
(White bars, n=59) were graphed as figure 4C and 4D. Bars represent geomeans 695% CI. * Indicates significant differences (p#0.05) between 2
study groups.
doi:10.1371/journal.pone.0028680.g004
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considered as an important player in the pathogenesis and disease
development based on the following known observations. The
invasion of P(H1N1) influenza virus into the lung tissues of
mammals induces the production of pro-inflammatory cytokines
and results in the development of pneumonia. In mice infected
with P(H1N1) virus, the productions of IFN-c, IL-4, IL-5, and IL-
10 were increased. In macaques infected with P(H1N1), the levels
of IL-6 and IL-18 were higher than those of non-infected ones [1].
In the homogenates of mouse lungs, the levels of the Th2
cytokines, notably IL-4, IL-5, and IL-10, were selectively induced
after P(H1N1) infection [1]. In our current study, we collected sera
from P(H1N1) patients to study the host innate immune response
of the prodromal period to P(H1N1) infection. Comprehensive
and strong cytokine induction in the early P(H1N1) infection with
the higher level of sera IL-2, IL-12, IFN-c, IL-6, TNF-a, IL-5, IL-
10, IL-17 and IL-23 were observed.
Among the different cytokines analyzed in our study, the sera
levels of IL-6 and IL-10 were considerably higher in the P(H1N1)
patients than that of the non-ILIs infection patients and the
healthy controls. We also observed that with the progression of
clinical severity, sera levels of IL-6 and IL-10 in the study subjects
were significantly up-regulated, with the lowest levels in the
healthy controls, higher levels in the mild P(H1N1) patients and
the highest levels in the severe P(H1N1) patients. In addition, the
vaccinees who had HI antibody to P(H1N1) displayed markedly
increased level of sera IL-10 compared to that of the healthy
controls. Therefore, the roles of both IL-6 and IL-10 in P(H1N1)
infection were indicated. As one of the important proinflammatory
cytokines, IL-6 was elevated in patients with inflammatory
diseases. IL-6 is induced by inflammatory stimuli, such as IL-1
and TNF-a [17]. IL-10 acts as a major immunomodulatory
cytokine. It can inhibit antigen-presenting cells (APC) and
macrophage function, suppress Th1 cytokine production and
impair T-cell responses. IL-10 can also induce immune anerge
[16] and differentiation of regulate T cell [18]. Previous study
suggested that both IL-10 and IL-6 mainly act via the Janus
kinases (Jaks) and STAT signal transduction pathway and may
share some common biological activities [19]. IL-6 was identified
as the inducer of IL-10 production to some extent [20]. They may
function in concert to clear pathogens and regulate cellular
immune responses, which are critical for the host to protect against
lethal influenza, however, resulting in destructive tissue inflam-
mation.
The P(H1N1) patients from year 2009 were febrile travelers
quarantined at the entry of Shanghai from outside of China. Most
of them were still at the prodromal stage of the disease. During the
initial response to P(H1N1) virus, the host macrophages may
Figure 5. The associations between IL-6 level and body temperature, and between IL-6 and IL-10. Associations of the of body
temperature (graph 6A) and production of IL-10 (graph 6B)) together with sera IL-6 levels in mild P(H1N1) patients from year 2009 were analyzed
using Pearson correlation. Correlations of the of body temperature (graph 6C) and production of IL-10 (graph 6D)) together with sera IL-6 levels in
severe P(H1N1) patients from year 2011 were analyzed using Pearson correlation. The ‘‘r’’ (correlation coefficient) and p values are indicated on
respective graphs obtained from the correlation analysis.
doi:10.1371/journal.pone.0028680.g005
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stimulate the immune response that leads to the symptoms of
inflammation. This is evidenced by the fact that mild P(H1N1)
patients suffered from higher fever (Figure 6A), elicited more
potent production of pro-inflammatory cytokines such as IFN-c,
TNF-a and IL-6 (Figure 1A and 1B) than the non-ILIs cases.
Therefore, the increased level of IL-6 in mild P(H1N1) cases
(27.5 pg/ml ) compared to that of the healthy controls (8.8 pg/ml )
may relate to fever and the acute response since strong correlation
between patients’ sera IL-6 and body temperature was observed
(Figure 6A). It is possible that with the progression of the disease,
the anti-inflammatory cytokines were produced to limit the extent
of the pro-inflammatory activities. This is supported by the
observation that severe P(H1N1) patients did not experience
higher fever than the severe non-ILIs. Up-regulated level of sera
IL-6 in the severe P(H1N1) patients ( 10.0-fold, 88.0 pg/ml in
severe cases in contrast to 8.8 pg/ml in the healthy ones) may
mainly be caused by the activation of IL-10 production (4.2-fold,
10.01 pg/ml in severe cases in contrast to 2.39 pg/ml in healthy
ones). This is evidenced by the strong correlation between sera
levels of IL-6 and IL-10 (Figure 6D), together with the poor
association between IL-6 production and body temperature
(figure 6C) in severe P(H1N1) patients. IL-6 may also promote
IL-10 function, as evidenced by the phenomenon that severe
P(H1N1) cases produced significant lower level of sera pro-
inflammatory cytokines, such as IFN-c (p=0.022), TNF-a
(p=0.033) and IL-5 (p=0.001), as compared to the mild patients.
Furthermore, we found that the severe P(H1N1) patients more
frequently experienced productive cough and diarrhea than the
severe non-ILIs. However, more severe non-ILIs suffered from dry
cough than the severe P(H1N1) ones (Table 1). This raised the
possibility of viral persistence or secondary infection resulted from
immunosuppression mediated synergistically by IL-6 and IL-10.
Our results are consistent with the results from a study using an
animal model infected with seasonal influenza A virus [21]. They
found that the production of IL-10 did not impact virus clearance
and disease recovery at a low virus dose. Instead, production of IL-
10 was detrimental and dramatically reduced mice survival during
lethal-dose virus challenge [21]. The symptoms and fever
correlated with the release of IL-6 both in experimental models
and patients with naturally acquired acute seasonal influenza A
were observed in other studies. The up-regulation of the sera IL-10
level suggested a higher chance of disease persistence or secondary
opportunistic infection in P(H1N1) infection. Thus the immuno-
suppressive environment created by IL-10 in synergism with IL-6
may lead to the virus persistence or secondary infection, which
may result in the more severe symptoms in the severe P(H1N1)
patients. In our present study, the 9 severe P(H1N1) patients are all
children. It is known that the innate immune system functions
differently in children as compared to adults. Therefore, more
studies are needed for better insights. Despite of this our results still
provide new understanding of the P(H1N1) pathogenesis, and
warrant further investigations in adult severe P(H1N1) patients.
In a study of cytokine profile of P(H1N1) infection, O ¨ sterlund
et al [8] and his colleagues used a typical North American/
European lineage of P(H1N1) virus to infect human monocyte-
derived DCs and macrophages in vitro. Their results showed that
P(H1N1) induced a relatively weak innate immune response in
these cells. Moreover, Mukherjee et al [9] studied the host gene
expression response to an Indian isolate of P(H1N1) infection in
A549 cells using a microarray platform. They found that P(H1N1)
infection resulted in considerable downregulation of the expression
of cytokines, namely IL-8, and IL-4, compared to seasonal H1N1.
A resent research on cytokine levels in P(H1N1) infected humans
was performed in Romania [22]. They detected IL-6, IL-8, IL-12,
IL-17, TNF-a and IFN-c in both mild and severe P(H1N1)
Figure 6. The schematic diagram summarizing the association observed in this study. The schematic diagram was designed to describe
the innate immune response of individuals who have been immunized with the pandemic H1N1 influenza vaccine, infected with P(H1N1) virus, or
infected with other non-influenza respiratory agents. The sera cytokines and chemokine secretion status serve as indicators of the innate immune
response. qIndicates markedly up-regulated cytokine levels; qqIndicates robust up-regulated cytokines levels.
doi:10.1371/journal.pone.0028680.g006
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reported significantly higher levels of sera IL-6, IL-12, IP-10 and
TNF-a in the mild P(H1N1) patients than those of healthy
controls,. different from our observation of a comprehensive
innate immune response in mild P(H1N1) patients with up-
regulated levels of sera IL-2, IL-12, IFN-c, IL-6, TNF-a, IL-5, IL-
10, IL-17 and IL-23. The difference might be due to the sample
types between Romania study and ours. First the age median of
the Romania mild P(H1N1) patients was 33 years old (IQR,18 to
35), and 64% (7/11) of them had other diseases, such as
cardiovascular disease, asthma/COPD, obesity and cancer. While
the age median in our study was 16 (IQR, 21–27), and, 6% (5/77)
mild P(H1N1) patients had underlying diseases. The other diseases
in Romania mild P(H1N1) patients may impact their innate
immune response to some extent and affected their cytokine
profiles. Second, the sera collection time after P(H1N1) infection
might also contribute the difference. We collected the patient sera
sample at the date of fever onset (during the prodromal period of
disease), while the sera samples in Romnia were collected 2 days
(IQR 2 to 3) after the onset of illness, which is the host innate
immune response in a later stage of the disease. Previous in vitro
study observed that T-cell activation and proliferation genes
expression increased at the early stages, but no changes at the later
stages in P(H1N1) infected human DC [9]. Third, in the Romania
study, there were only 11 mild and hospitalized (more serious
clinical symptoms) patients. In our present study, a total of 77 mild
P(H1N1) patients were investigated. Taken together, all the above
factors may have affected the different cytokine profiles between
the Romania patients and those in our study.
Concluding remarks
Our observations provide new evidence that a comprehensive
innate immune response is activated at the early stage of pandemic
H1N1 influenza virus infection with up-regulated production of
sera IL-2, IL-12, IFN-c, IL-6, TNF-a, IL-5, IL-10, IL-17 and IL-
23. With disease progression, higher levels of sera IL-6 and IL-10
were found in severe pandemic H1N1 influenza patients. We
further identified a strong correlation between IL-6 and IL-10
production in the severe P(H1N1) patients. Significantly elevated
IL-10 secretion in the P(H1N1) vaccinees further confirmed our
conclusion that highly elevated levels of sera IL-6 and IL-10 in
P(H1N1) patients may lead to disease progression and severity.
And the increased IL-6 and IL-10 levels may together be the
underlying cause of the observed clinical severity in the severe
P(H1N1) patients. In-depth underlying mechanisms await further
detailed investigations in the future. The findings of this study are
concluded into Figure 6.
Materials and Methods
Study Subjects
1) Patient with mild symptoms. In Shanghai, the instituted
health monitoring by temperature screening was implemented in
2009 at all ports of entry for travelers arriving from areas or
countries heavily affected by pandemic H1N1 virus. According to
the requirement of ‘‘Interim Guidance on Infection Control Measures for
2009 H1N1 Influenza’’ issued by the Chinese Center for Disease
Control and Prevention (CCDC) [23], any travelers who were
experiencing acute respiratory illness and fever (body
temperature$37.5 degrees Celsius) were isolated from the
healthy population. The throat/nose swab and blood samples of
the illed travelers were taken based on informed consent. All
samples were sent to the microbiology laboratory of Shanghai
Municipal Center for Disease Control and Prevention (SCDC) for
influenza virus detection. Subsequently, experienced public health
staff interviewed case patients by a standardized questionnaire to
determine symptoms at the time of sample collection. This
information was entered into SCDC database. All samples were
analyzed for influenza A, B and subtypes of A by influenza real-
time RT-PCR test. A total of 77 serum samples from patients with
confirmed P(H1N1) infection and 59 serum from non-ILIs patients
were taken. Both groups were of mild symptoms.
2) Patients with severe symptoms. In 2011, a total number
of 25 throat swabs and blood samples from hospitalized
pneumonia patients were sent to our laboratory by their parents
for influenza analysis. Nine of them were positive for P(H1N1)
detection, and the rest 16 negative for human influenza A and B
virus detection by influenza real-time RT-PCR test.
3) P(H1N1) vaccinees and healthy study subjects. According
to the Immunization Strategy [24] issued by CCDC, from September
15, 2009, public servants at key positions (e.g., health staff), being the
high priority populations, were administered with the P(H1N1)
vaccine under the principles of inform consent, voluntary and free of
charge. Before vaccination and after vaccination (1, 6 and 12 months
post), blood samples were collected from the randomly selected
subjects who accepted immunization from their county CDCs [25].
Case demographic and epidemiological information was investigated
at the same time of sample collection. All blood samples from
Shanghai were transported to and stored in the SCDC Mass Vaccination
Surveillance Sample Bank (SCDC MVSSB) for analysis. We randomly
selected 26 sera samples before vaccination with a Hemagglutinin
Inhibition (HI) antibody titer for pandemic H1N1 virus lower than
40 IU/ml as healthy controls, and 26 sera samples 1 month after
vaccination with a HI antibody titer for pandemic H1N1 virus higher
than 40 IU/ml for the P(H1N1) vaccinees.
Influenza Real-time RT-PCR
The total nucleic acid of each swab (200 ml) was isolated using
the MagNA Pure LC 2.0 Instrument (Roche Diagnostics Ltd,
Switzerland) and a MagNA Pure LC DNA Isolation Kit (Roche
Diagnostics GmH, Germany) following manufacturer’s recom-
mendations. Sixty micro liter of eluted and purified DNA was
stored at 4uC and used as templates for PCR within 4 hours.
Influenza Real-time RT-PCR was performed in all swabs using
primers and probes described in the CCDC A(H1N1) influenza
guidance.
CBA Assays
Sera IL-2, IL-4, IL-5, IL-10, TNF-a and IFN-g levels were
evaluated using the cytokine bead array (CBA) and the Human
Th1/Th2 Cytokine CBA kit(BD Biosciences, San Jose, CA, USA).
IL-1, IL-6, IL-8, IL-12 levels were assayed using a Human
Inflammatory Cytokine CBA kit (BD Biosciences, San Jose, CA,
USA). Bead populations with distinct intensities coated with
capture antibodies specific for each cytokine and chemokine were
mixed and added to each assay tube, followed by Phycoerythrin
(PE) detection reagent and plasma. Mixtures were incubated at
room temperature for 3 hrs in darkness, washed, and then
analyzed using a flow cytometry (Falcon; BD Biosciences). Data
were analyzed using the BD CBA analysis software. The
individual cytokine concentration of each test sample was
calculated against the reference to a standard curve. Data were
log transformed, and geomeans 695%CI are shown in the figures.
Cytokines ELISA
Sera IL-17 and IL-23 levels were analyzed using a commercial
Human Il-17 ELISA Kit and the Human IL-23 ELISA Kit
(ABCAM, US). Experiments were performed according to the
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determined by comparison with a standard curve. Cytokine levels
were measured as duplicates and averaged.
Statistical Analyses
All data were processed using SPSS for Windows version 13.0.
Differences in age ratio among different disease groups and body
temperature were analyzed using the nonparametric Kruskal-
Wallis chi-square test. Gender distribution was analyzed using the
Pearson chi-square test. Since the data of cytokine levels were
highly variable, the values were log transformed. The geomean
and its 95% CI were then calculated and independent t-test was
performed to detect the differences based on the log transformed
data. Statistic significance was considered when p value is equal or
less than 0.05.
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